Jove
Visualize
Contact Us

Related Experiment Videos

Which Drug Next? Sequential Therapy for Osteoporosis.

Barbara P Lukert1

  • 1Division of Endocrinology, Metabolism & Genetics, Department of Medicine, University of Kansas School of Medicine, Kansas City, Kansas.

The Journal of Clinical Endocrinology and Metabolism
|January 11, 2020
PubMed
Summary

New osteoporosis drugs offer benefits but require follow-up treatments. Alendronate effectively preserves bone gained during denosumab therapy, preventing rapid bone loss after treatment cessation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Sex and Gender in Transgender Bone and Other Musculoskeletal Health.

The Journal of bone and joint surgery. American volume·2024
Same author

Sclerotic bone changes on densitometry testing in a patient with a remote history of breast cancer.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2008
Same author

Editorial: glucocorticoid replacement--how much is enough?

The Journal of clinical endocrinology and metabolism·2006
Same author

Osteoporosis associated with excess glucocorticoids.

Endocrinology and metabolism clinics of North America·2005
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Endocrinology
  • Bone Biology
  • Pharmacology

Background:

  • Osteoporosis treatment has evolved with new drugs beyond bisphosphonates (BPs).
  • Concerns about long-term bisphosphonate complications have shifted prescribing practices.
  • Novel osteoporosis medications (e.g., denosumab, romosozumab) offer unique mechanisms but pose challenges like rapid bone loss post-treatment.

Purpose of the Study:

  • To evaluate the efficacy of alendronate in preserving bone mass after denosumab treatment.
  • To address the challenge of bone loss following withdrawal of bone-building osteoporosis therapies.

Main Methods:

  • The study investigated the effect of alendronate administration following denosumab therapy.
  • Bone mineral density changes were assessed in patients transitioning between these treatments.
Keywords:
anabolic agentsanti-resorptive agentsdenosumabosteoporosis

Related Experiment Videos

Main Results:

  • Alendronate successfully preserved bone mass that was accrued during denosumab treatment.
  • This indicates that alendronate can mitigate the rapid bone resorption that occurs after denosumab withdrawal.

Conclusions:

  • Transitioning from denosumab to alendronate is an effective strategy to maintain bone gains.
  • This approach helps manage osteoporosis by preventing rebound bone loss and sustaining therapeutic benefits.